These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32854252)

  • 1. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of
    Ghannoum M; Arendrup MC; Chaturvedi VP; Lockhart SR; McCormick TS; Chaturvedi S; Berkow EL; Juneja D; Tarai B; Azie N; Angulo D; Walsh TJ
    Antibiotics (Basel); 2020 Aug; 9(9):. PubMed ID: 32854252
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Arendrup MC; Jørgensen KM; Hare RK; Chowdhary A
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrexafungerp Demonstrates
    Wiederhold NP; Najvar LK; Olivo M; Morris KN; Patterson HP; Catano G; Patterson TF
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753333
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.
    Jallow S; Govender NP
    J Fungi (Basel); 2021 Feb; 7(3):. PubMed ID: 33668824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date.
    Colombo RE; Vazquez JA
    Expert Opin Pharmacother; 2021 May; 22(7):797-807. PubMed ID: 33599551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against
    Gamal A; Chu S; McCormick TS; Borroto-Esoda K; Angulo D; Ghannoum MA
    Front Cell Infect Microbiol; 2021; 11():642358. PubMed ID: 33791244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrexafungerp: A new triterpenoid antifungal.
    Sucher AJ; Thai A; Tran C; Mantena N; Noronha A; Chahine EB
    Am J Health Syst Pharm; 2022 Dec; 79(24):2208-2221. PubMed ID: 36083109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method.
    Mesquida A; Díaz-García J; Sánchez-Carrillo C; Muñoz P; Escribano P; Guinea J
    Clin Microbiol Infect; 2022 Jan; 28(1):140.e1-140.e4. PubMed ID: 34619396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris.
    Jenull S; Shivarathri R; Tsymala I; Penninger P; Trinh PC; Nogueira F; Chauhan M; Singh A; Petryshyn A; Stoiber A; Chowdhary A; Chauhan N; Kuchler K
    mBio; 2022 Aug; 13(4):e0079922. PubMed ID: 35968956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Second-Generation Fungerp Analog, SCY-247, Shows Potent
    Chu S; Long L; Sherif R; McCormick TS; Borroto-Esoda K; Barat S; Ghannoum MA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33317999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
    Larkin E; Hager C; Chandra J; Mukherjee PK; Retuerto M; Salem I; Long L; Isham N; Kovanda L; Borroto-Esoda K; Wring S; Angulo D; Ghannoum M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223375
    [No Abstract]   [Full Text] [Related]  

  • 12.
    Nunnally NS; Etienne KA; Angulo D; Lockhart SR; Berkow EL
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
    Azie N; Angulo D; Dehn B; Sobel JD
    Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
    Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
    [No Abstract]   [Full Text] [Related]  

  • 15. Rezafungin
    Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.
    Angulo DA; Alexander B; Rautemaa-Richardson R; Alastruey-Izquierdo A; Hoenigl M; Ibrahim AS; Ghannoum MA; King TR; Azie NE; Walsh TJ
    J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates.
    Dong J; Liang G; Zheng H; Kan S; Song N; Zhang M; Liu W
    Mycoses; 2021 Jun; 64(6):651-655. PubMed ID: 33609301
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Zhu Y; Kilburn S; Kapoor M; Chaturvedi S; Shaw KJ; Chaturvedi V
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839219
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Hager CL; Larkin EL; Long L; Zohra Abidi F; Shaw KJ; Ghannoum MA
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311065
    [No Abstract]   [Full Text] [Related]  

  • 20. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.
    Lockhart SR; Etienne KA; Vallabhaneni S; Farooqi J; Chowdhary A; Govender NP; Colombo AL; Calvo B; Cuomo CA; Desjardins CA; Berkow EL; Castanheira M; Magobo RE; Jabeen K; Asghar RJ; Meis JF; Jackson B; Chiller T; Litvintseva AP
    Clin Infect Dis; 2017 Jan; 64(2):134-140. PubMed ID: 27988485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.